PolyPid (PYPD) Share-based Compensation (2021 - 2025)
PolyPid (PYPD) posted Share-based Compensation of $6.9 million for Q2 2025, up 9.56% sequentially from $6.3 million in Q2 2024, and up 9.56% YoY from $6.3 million in Q2 2024.
PolyPid (PYPD) Share-based Compensation (2021 - 2025) Analysis & Trends
PolyPid has reported Share-based Compensation for 5 years, with the latest figure at $6.9 million in Q2 2025.
- Quarterly Share-based Compensation rose 9.56% year-over-year to $6.9 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $6.9 million (up 9.56% YoY) and the FY2025 annual result came in at $4.9 million, up 71.88% from the prior year.
- Share-based Compensation improved to $6.9 million in Q2 2025 per PYPD's latest filing, from $6.3 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $6.9 million in Q2 2025 and troughed at $841000.0 in Q2 2023.
- A 5-year average of $3.3 million and a median of $1.3 million in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation tumbled 33.57% in 2023, then surged 649.7% in 2024.
- Over 5 years, Share-based Compensation stood at $1.2 million in 2021, then rose by 9.8% to $1.3 million in 2022, then sank by 33.57% to $841000.0 in 2023, then soared by 649.7% to $6.3 million in 2024, then increased by 9.56% to $6.9 million in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $6.9 million, $6.3 million, and $841000.0 for Q2 2025, Q2 2024, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | PolyPid | 113.30 Mn | 106.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 6.91 Mn |
| Jun 30, 2025 | 6.91 Mn |
| Jun 30, 2024 | 6.31 Mn |
| Jun 30, 2024 | 6.31 Mn |
| Jun 30, 2023 | 841,000.00 |
| Jun 30, 2023 | 841,000.00 |
| Jun 30, 2022 | 1.27 Mn |
| Jun 30, 2022 | 1.27 Mn |
| Jun 30, 2021 | 1.15 Mn |
| Jun 30, 2021 | 1.15 Mn |